UASt regulatory sequences drive expression of BicD that has been mutated to carry the S103L amino acid replacement (this is equivalent to p.BICD2Ser107Leu in the human BICD2 ortholog, which is identified as a frequent mutation in individuals with autosomal dominant lower extremity-predominant spinal muscular atrophy 2). The protein is tagged at the C-terminal end with one copy of Tag:FLAG.
TC17464477CT
TCC>CTC
S103L | BicD-PA; S103L | BicD-PB; S103L | BicD-PC; S103L | BicD-PD
S103L
Analogous S107L mutation in human BICD2 implicated in spinal muscular atrophy, lower extremity-predominant, 2; mutation carried on in vitro construct.
The disease model is observed when BicDS103L.UAS.Tag:FLAG is expressed (in a BicDr5/+ background) in neuronal tissue (using Scer\GAL4nSyb.PS) but not when it is expressed in muscle (using Scer\GAL4Mef2.PR).
Expression of BicDS103L.UAS.Tag:FLAG under the control of Scer\GAL4nSyb.PS significantly reduces adult male climbing ability in a BicDr5/+ background, but not in a +/+ background, compared to controls; there is also a significant decrease in larval neuromuscular junction size in a BicDr5/+ background, compared to controls.
Expression of BicDS103L.UAS.Tag:FLAG under the control of Scer\GAL4Mef2.PR slightly, but significantly improves adult male climbing ability in a BicDr5/+ background, compared to controls.